Impax

Impax Laboratories Faces Sharp Decline After Profit Warning Linked to Tariff Issues

2 months ago

Shares of Impax Laboratories, a prominent player in the pharmaceutical industry, experienced a staggering drop of over 20% following a critical announcement regarding expected profits. The company attributed this downturn to escalating trade tensions and tariffs that are anticipated to severely impact its financial outlook.

Impax Asset Management Faces Major Setback with $6 Billion Mandate Loss

4 months ago

In a surprising turn of events, Impax Asset Management has announced the unexpected loss of a significant $6 billion investment mandate, a development marked as a significant setback by the company’s CEO, Ian Simm. This substantial financial shift signals a challenging phase for the asset management firm, which has built its reputation on sustainable investment strategies.

Impax Asset Management to Expand Credit Exposure in $50 Billion Portfolio

7 months ago

In a strategic shift aimed at enhancing investment returns, Impax Asset Management, a leading global investment firm, announced its decision to significantly increase its credit exposure within its extensive $50 billion portfolio. This move comes at a time when the firm seeks to capitalize on the current market environment, which presents unique opportunities for discerning investors.